Through Proven Connect, PCR will co-invest with venture capital funders and impact investors and connect companies to the resources and expert support they need to succeed. [This programme is already supporting the delivery of breakthroughs, with funding for Cambridge spin-out Lucida Medical supporting the development of its machine learning software for prostate cancer detection from MRI.] PCR aims to generate a substantial increase in equity funding for early-stage companies that are working on treatments, diagnostics and services that tackle prostate cancer.”

Oliver Kemp, Chief Executive of PCR said “Too many promising innovations fail to make the leap into the clinic. It’s incredibly important that we continue to support new approaches to the diagnosis, care and treatment of prostate cancer patients right through to patients in the clinic.”